Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cipla is planning to invest INR50 crore ($89.9m) to build active pharmaceutical ingredients (API) facilities at Patalganga, Mumbai, Bengaluru, Karnataka, and Kurkumbh, Pune, India.
Subscribe to our email newsletter
The API facilities are expected to be completed by 2012-13, reports business-standard.
Through its partners in China, the company is also involved in developing bio- similars/ bio-therapeutic products and the clinical trials on these drugs are expected to be completed in 2-3 years and will be launched in India.
The company said its venture into stem cell-based products is under progress with a major investment in Stempeutics Research, with a launch expected in three years.
In Europe, Cipla is expanding its presence in the inhaler segment with regulatory approvals for a few products already in place and few more in the pipeline, while in the US, the company is exploring all options including filing its own abbreviated new drug applications (ANDAs).